SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX
SLXP
|
|
|
+126.17%
in
199 days
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Favorable risk / reward profile
SLXP
From the Blogosphere
Salix Beats on Xifaxan Strength – Analyst Blog
|
|
|
Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 15 cents per share in the third quarter, which was significantly better than the Zacks Consensus Estimate of a net loss of 29 cents. The company reported a net loss of 11 cents in the year-ago period. Although revenue increased from the year-ago period, higher operating expenses led to the year-over-year increase in net loss.
Total product revenue was $65.7 million, up 53%. Xifaxan continued to perform well with revenue almost doubling to $42.7 million. We believe wholesaler stocking, price increases and prescription growth were respo...
|
Unusual 11 Mid-Day Movers 9/14: ZOOM, SLXP, BRNC, HDY Higher; AMIE, ALXA, ALTI, CDE Lower
|
Zoom Technologies, Inc. (NASDAQ: ZOOM) <font>84.2% HIGHER;</font> surging higher today after announcing the results of its recently approved acquisition, Gold Lion. The newly acquired company reported Q2 revenue increased 354% to $53.1 million; net income in the quarter grew to to $1.7 million, versus a net loss of $0.1 million last year; Gold Lion management's FY09 net revenue guidance in the range of $145-$155 million, versus $81 million in 2008; Gold Lion management's FY09 net income guidance in the range of $5.9-$6.1 million, versus $2.8 million in 2008.Salix Pharmaceuticals, Ltd. (NASD...
|
Morning Movers 9/14: SLXP, S, KERX, ARIA, HDY Higher; ALXA, EE, SAH, CWTR Lower
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) <font>54.4% HIGHER;</font> announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). Click here for the full report.Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) <font>30% LOWER;</font> announced preliminary results from its 366 patient Phase 2b clinical trial of AZ-104 in patients with migraine headache. Both AZ-104...
|
Challenges for Sell-Rated Salix
SLXP
-217.92%
in
536 days
We expect 2008 to be an extremely challenging year for the company with a significant decline in both revenues and earnings.
|
MFI Shortbusters for May 2008
|
|
|
This month's MFI Shortbusters portfolio is as follows:
* appeared in last month's MFI Shortbusters screen
As a reminder, the Shortbuster criteria is as follows:
- Shares Short as a Percentage of Float >= 20
- Shares Short Current Month <= Shares Short Prior Month
The first Shortbusters portfolio will have aged to the one-year holding period next month, so look for performance updates to begin at that point.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on SLXP |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Salix Pharmaceuticals Ltd.
- Answers.com
